Menu Search
Equities

Cellectis SA

CLLS:NMQ

Cellectis SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.77
  • Today's Change0.02 / 1.14%
  • Shares traded32.22k
  • 1 Year change-29.20%
  • Beta3.0477
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy5
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Cellectis SA (ADR) have a median target of 5.50, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a 210.73% increase from the last price of 1.77.
High465.0%10.00
Med210.7%5.50
Low69.5%3.00

Earnings history & estimates in USD

On Nov 04, 2024, Cellectis SA (ADR) reported 3rd quarter 2024 losses of -0.23 per share. This result was in line with the consensus of the 6 analysts following the company and exceeded last year's 3rd quarter results by 25.81%.
The next earnings announcement is expected on Mar 10, 2025.
Average growth rate-53.97%
Cellectis SA (ADR) reported annual 2023 losses of -1.77 per share on Apr 29, 2024.
Average growth rate+4.98%
More ▼

Revenue history & estimates in USD

Cellectis SA (ADR) had 3rd quarter 2024 revenues of 18.05m. This bettered the 5.40m consensus of the 4 analysts covering the company. This was 407.16% above the prior year's 3rd quarter results.
Average growth rate+95.94%
Cellectis SA (ADR) had revenues for the full year 2023 of 9.19m. This was 64.26% below the prior year's results.
Average growth rate+28.52%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.